Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxycycline hyclate - Aqua Pharmaceuticals

Next Previous
Drug Profile

Doxycycline hyclate - Aqua Pharmaceuticals

Alternative Names: ACTICLATE; ACTICLATE CAP; AQ101; Doxycycline hyclate USP; Monodox

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aqua Pharmaceuticals
  • Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Amoebiasis; Anthrax; Bacterial infections; Borrelia infections; Brucellosis; Campylobacter infections; Chancroid; Chlamydial infections; Cholera; Clostridium infections; Escherichia coli infections; Fusobacterium infections; Gonorrhoea; Gram-negative infections; Gram-positive infections; Haemophilus infections; Klebsiella infections; Listeria infections; Malaria; Plague; Pneumonia; Rickettsia infections; Shigella infections; Urethritis

Most Recent Events

  • 26 Apr 2016 Registered for Anthrax, Borrelia infections, Brucellosis, Campylobacter infections, Chancroid, Chlamydial infections, Cholera, Escherichia coli infections, Gonorrhoea, Haemophilus infections, Klebsiella infections, Plague, Pneumonia, Rickettsia infections, Shigella infections and Urethritis, Clostridium infections (treatment-experienced), Listeria infections (treatment-experienced) and Malaria (treatment-experienced), Acne (adjunctive treatment), Gram-positive infections, Gram-negative infections and Bacterial infections in USA (PO, Capsule)
  • 31 Aug 2014 Launched for severe Acne (Adjunctive treatment) in USA (PO) - First Global Launch
  • 28 Jul 2014 Registered for Acne (adjunctive treatment) in USA (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top